Search - tctmd.com

Displaying 41 - 60 of 142

Sort: Relevancy | Date

News Daily News

Fewer Diagnostic Tests, Higher CV Mortality During COVID-19 Pandemic

Michael O'Riordan

January 12, 2021

News Daily News

US Cath Labs and COVID-19: Pushed Procedures, Late STEMIs, and Paycheck Pain

Shelley Wood

September 17, 2020

News Daily News

Coronary CTA Should Be First When Assessing Stable CAD: Consensus Document

Yael L. Maxwell

September 10, 2020

News Features

Walloped by COVID-19, US Cardiology Practices Brace for Slow Recovery

Todd Neale

July 29, 2020

News Conference News SCCT 2020

For Cardiac CT, COVID-19 Has Toppled Silos and Paved the Way for Change

Yael L. Maxwell

July 28, 2020

News Conference News SCCT 2020

Biggest Barriers to Cardiac CT? Old Myths, Fair Payment, and De-adoption

Yael L. Maxwell

July 22, 2020

News Conference News ACC 2020

More Symptoms, Less Extensive Disease in Women With Stable CAD: ISCHEMIA

Michael O'Riordan

March 28, 2020

News Opinion Conversations in Cardiology

Conversations in Cardiology: In the ISCHEMIA Era, What Role for FFR?

January 02, 2020

News Features

Year in Review: Payment Fights, Wearables, Burnout Defined Cardiology Practice in 2019

Caitlin E. Cox

December 17, 2019

News Daily News

Counting CPCs May Beat Stress Tests for Stratifying CAD Risk

Yael L. Maxwell

December 11, 2019

News Conference News AHA 2019

ISCHEMIA: Invasive Strategy No Better Than Meds for CV Events

Shelley Wood

November 16, 2019

News Conference News AHA 2019

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

Michael O'Riordan

November 14, 2019

News Conference News AHA 2019

ISCHEMIA Countdown Begins, but a ‘Black-and-White’ Answer Is Uncertain

Shelley Wood

October 25, 2019

News Opinion Fellow Talk

Finding Your Best Fit in Cardiology

Arvind Reddy, MD

October 18, 2019

News Daily News

Believing SCOT-HEART: New Analysis Probes Plausible Mechanisms of Benefit

Shelley Wood

October 14, 2019

News

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

Michael O'Riordan

September 24, 2019

News Daily News

MI Definitions in SCOT-HEART Prompt Outcry—Then Silence—on Twitter

Shelley Wood

September 19, 2019

News Daily News

Echo Overuse in Heart Failure Stabilizes in the Wake of Ontario Appropriateness Efforts

Michael O'Riordan

August 09, 2019

News Conference News SCCT 2019

Doubling Down on SCOT-HEART: Mechanisms, Applicability, and Future Directions

Yael L. Maxwell

July 18, 2019

News Industry News

FDA approves Bayer's Gadavist® (gadobutrol) injection as the first and only contrast agent for use in cardiac MR in adult patients with known or suspected coronary artery disease

July 15, 2019

Advertisement

Fewer Diagnostic Tests, Higher CV Mortality During COVID-19 Pandemic

US Cath Labs and COVID-19: Pushed Procedures, Late STEMIs, and Paycheck Pain

Coronary CTA Should Be First When Assessing Stable CAD: Consensus Document

Walloped by COVID-19, US Cardiology Practices Brace for Slow Recovery

For Cardiac CT, COVID-19 Has Toppled Silos and Paved the Way for Change

Biggest Barriers to Cardiac CT? Old Myths, Fair Payment, and De-adoption

More Symptoms, Less Extensive Disease in Women With Stable CAD: ISCHEMIA

Conversations in Cardiology: In the ISCHEMIA Era, What Role for FFR?

Year in Review: Payment Fights, Wearables, Burnout Defined Cardiology Practice in 2019

Counting CPCs May Beat Stress Tests for Stratifying CAD Risk

ISCHEMIA: Invasive Strategy No Better Than Meds for CV Events

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

ISCHEMIA Countdown Begins, but a ‘Black-and-White’ Answer Is Uncertain

Finding Your Best Fit in Cardiology

Believing SCOT-HEART: New Analysis Probes Plausible Mechanisms of Benefit

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

MI Definitions in SCOT-HEART Prompt Outcry—Then Silence—on Twitter

Echo Overuse in Heart Failure Stabilizes in the Wake of Ontario Appropriateness Efforts

Doubling Down on SCOT-HEART: Mechanisms, Applicability, and Future Directions

FDA approves Bayer's Gadavist® (gadobutrol) injection as the first and only contrast agent for use in cardiac MR in adult patients with known or suspected coronary artery disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content